Autoantibodies appear during severe COVID-19 illness: MedRxiv

A preprint (not yet peer-reviewed) article (.pdf full-text version here) appeared on MedRxiv on October 23, 2020 that described the frequent presence of autoantibodies in patients with severe COVID-19 disease.

In these patients, critically ill with COVID-19, more than half showed autoantibodies to a variety of normal constituents of the cell. Some factor that contributes to serious COVID-19 illness also results in the development of autoantibodies.

This has relevance to treatment, explaining why dexamethasone (which suppresses immune reactions) is so effective in severe disease, and suggesting that additional immune suppressive treatments may be helpful.

This also has relevance to explaining why some patients have persistent symptoms long after the viral infection has resolved. Autoantibodies may be causing brain cell damage, damage to both skeletal and heart muscle, and lung problems. Further research will clarify this issue.

Prior to this research, there were findings that anti-interferon antibodies were present in 10% of patients with severe COVID-19 pneumonia. This underscores the importance of interferon in mediating the systemic response to coronavirus infection. (See this article in Science magazine if you dare to learn too much about this.)

The research described in the paper we are talking about today involved 52 patients, almost all of them critically ill with COVID-19 (only two were described as “severe.”) Two-thirds of the patients were male, and 54% of them were African-American (this corresponds to the demographics of serious COVID-19 infections generally– most patients are nonwhite men.)

None of the patients in this study had a prior history of auto-immune disease such as systemic lupus erythematosus or rheumatoid arthritis. Most of the patients had extremely high C-reactive protein (CRP) levels, from 17 to 473 (normal is less than 10; CRP almost always is high– though not this high– in the presence of any infection or inflammation.)

23 of the patients had positive anti-nuclear antibody (ANA) tests, 19 of them with titers of 1:160 or worse (positive ANA is normally found in the setting of lupus erythematosus.) Follow-up testing in seven patients, two weeks later, included four with positive ANA at the outset; one with a titer of 1:80 had resolved at follow-up, but the other three showed 1:360 or worse, one increasing to 1:2560.

Twelve of the patients showed positive rheumatoid factors (RF) (normally seen in rheumatoid arthritis), and ten showed a variety of other autoantibodies (normally seen in other auto-immune diseases.) Some of the patients had both rheumatoid factor and ANA autoantibodies; the number with both is unclear from the figures.

Details of the autoantibodies are shown in Table 1 and Figure 1 of the full-text version of the paper. There are some inconsistencies in the data shown, no doubt due to the fact that the paper has not been reviewed or editorially corrected.

The conclusion of the paper states:

Our findings invite two interpretations. Either patients with undocumented and pre-existing autoimmunity comprise the majority of the critical illness within our Atlanta-based cohort, or more likely, the immunological environment of serious COVID-19 infection, including TLR7 activation by SARS-CoV2 ssRNA [single-stranded ribonucleic acid], is sufficient to drive de novo autoreactivity against a variety of self-antigens.

The latter possibility has been documented in the setting of other serious infections (reference 10: Isenberg, D.A., et al. “Profile of autoantibodies in the serum of patients with tuberculosis, klebsiella and other gram-negative infections” Clin Exp Immunol 67, 516-523 (1987)), and is now mechanistically supported through independent validation of autoimmune-prone EF [extra-follicular] response activation in serious disease (reference 6: Kaneko, N., et al. “Loss of Bcl-6-Expressing T Follicular Helper Cells and Germinal Centers in COVID-19” Cell (2020)).

These findings may be consequential for the identification of patients in whom immunomodulation may be beneficial and suggest the value of autoreactivity measurements for proper segmentation and allocation of properly targeted therapies.

They further suggest that simple clinical testing for ANAs or RF may be able to distinguish those groups. Longitudinal study of recovered patients will be critical in understanding the persistence of this autoreactive state, its role in the increasingly documented cases of ‘lingering’ COVID-19 (reference 11: Carfi, A., Bernabei, R., Landi, F. & Gemelli Against, C.-P.-A.C.S.G. “Persistent Symptoms in Patients After Acute COVID-19” JAMA 324, 603-605 (2020)), and its propensity for conversion into self-sustaining autoimmunity– in order to devise early rheumatological intervention strategies and establish effective long-term care protocols.

https://www.medrxiv.org/content/10.1101/2020.10.21.20216192v1.full.pdf

In other words, testing for ANA and RF in serious cases of COVID-19 may identify patients who would benefit from immune-modifying drugs.